Israel Englander’s Viking Therapeutics VKTX Stock Holding History

Israel Englander’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,000	Closed	-$1.63M	–	6443
2026 Q1	$1.63M	Buy	+50,000	New	+$1.61M	﹤0.01%	4049
2025 Q3	–	Sell	-20,000	Closed	-$530K	–	6501
2025 Q2	$530K	Buy	+20,000	New	+$526K	﹤0.01%	4868
2025 Q1	–	Sell	-9,500	Closed	-$382K	–	6438
2024 Q4	$382K	Buy	9,500 +1,200	+14%	+$68.4K	﹤0.01%	4928
2024 Q3	$525K	Sell	8,300 -3,300	-28%	-$194K	﹤0.01%	4793
2024 Q2	$615K	Buy	+11,600	New	+$760K	﹤0.01%	4458
2023 Q4	–	Sell	-44,800	Closed	-$496K	–	6587
2023 Q3	$496K	Buy	44,800 +1,800	+4%	+$25.7K	﹤0.01%	4670
2023 Q2	$697K	Sell	43,000 -188,000	-81%	-$3.94M	﹤0.01%	4311
2023 Q1	$3.85M	Buy	231,000 +191,000	+478%	+$1.97M	﹤0.01%	2843
2022 Q4	$376K	Buy	+40,000	New	+$179K	﹤0.01%	4943

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Israel Englander's VKTX Position: Q2 2026 in Review

Israel Englander increased its Viking Therapeutics (VKTX) stake by 99% in Q2 2026, buying an estimated $8M and bringing the position to 498,172 shares worth $19.4M. The position accounts for 0.01% of the portfolio, ranked #1657.

Israel Englander first reported a position in VKTX in Q4 2017 and has held it in 30 quarters since. The position peaked at $63.9M in Q1 2023. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Israel Englander held 498,172 shares of Viking Therapeutics worth $19.4M as of Q2 2026.
Israel Englander bought 247,647 Viking Therapeutics shares in Q2 2026, an estimated $8M.
Viking Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1657 holding.
Israel Englander first reported a position in Viking Therapeutics in Q4 2017 and has held it in 30 quarters since.
Israel Englander's Viking Therapeutics position peaked at $63.9M in Q1 2023.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.